Genetic testing can assess the level of PD‐L1 expression in tumor cells, where vaccines, together with therapies focusing on the PD‐1 and TIGIT signaling pathways can help predict the potential response to immunotherapy.35 This evidence concerns the gene TIGIT and neoplasm.